Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Avoiding glucocorticoid administration in a neurooncological case.

Hans Peter Rutz1, Silvia Hofer, Pietro E Peghini

  • 1Division of Radiation Medicine, Paul Scherrer Institut, Switzerland. hanspeter.rutz@psi.ch

Cancer Biology & Therapy
|November 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic Value and Outcomes of Systematic SARS-CoV-2 Screening in Asymptomatic Patients.

JAMA network open·2026
Same author

High-Sensitivity Cardiac Troponin T-gen6 Assay in Suspected Myocardial Infarction: Diagnostic Accuracy, Cutoffs, and Clinical Implications.

Journal of the American College of Cardiology·2026
Same author

The cTnI/cTnT Ratio in Myocardial Injury: A Multicohort and Experimental Synthesis.

Journal of the American College of Cardiology·2026
Same author

Population pharmacokinetics of amikacin in patients with a haematological disorder: A prospective, observational study.

The Journal of infection·2026
Same author

Growth differentiation factor-15 in patients presenting with acute chest pain: Diagnostic and prognostic utility.

European journal of internal medicine·2026
Same author

A Novel N-Terminal Pro-B-Type Natriuretic Peptide Assay in the Early Diagnosis of Acute Heart Failure.

JACC. Advances·2025

Avoiding glucocorticoids (GCs) in brain tumor treatment may improve outcomes. Substituting dexamethasone with celecoxib successfully prevented brain edema in a glioblastoma patient, demonstrating potential for GC-sparing strategies.

Area of Science:

  • Neuro-oncology
  • Pharmacology
  • Cancer Research

Background:

  • Glucocorticoid (GC) use in solid tumors can improve outcomes but carries side effects.
  • Dexamethasone is commonly used for brain edema in glioblastoma multiforme (GBM).
  • Restricting GC use is desirable for improved patient outcomes.

Observation:

  • Celecoxib was administered instead of dexamethasone to prevent brain edema in a patient with cerebellar GBM.
  • Cerebrospinal fluid (CSF) celecoxib concentration was significantly lower than serum concentration.
  • A blood-CSF barrier limiting celecoxib penetration into the CSF was identified.

Findings:

  • The patient successfully avoided dexamethasone throughout treatment.
  • Celecoxib administration was effective in managing brain edema.

Related Experiment Videos

  • CSF celecoxib levels were substantially below those required for in vitro GBM cell inhibition.

    • Implications:

    • Non-steroidal anti-inflammatory drugs (NSAIDs) like celecoxib may offer an alternative to GCs for brain edema management in GBM.
    • Further clinical evaluation of brain-penetrant COX-2 inhibitors is warranted for GBM treatment.
    • Successful GC avoidance highlights the need for alternative therapies in neuro-oncology.